BioRestorative, University of Utah enter manufacturing deal
BioRestorative Therapies has signed a Material Manufacturing Agreement with the University of Utah in the US.
The University of Utah will manufacture certain materials derived from stem cells, as per the agreement.
The University of Utah Clinical Regenerative Medicine and Tissue Engineering director Amit Patel said they are expanding their relationship with BioRestorative Therapies and hope to assist the company in producing their stem cell derived materials.
BioRestorative Therapies chairman and CEO Mark Weinreb said the deal indicates the beginning of laboratory operations and expects additional research and clinical collaborations.
BioRestorative Therapies uses cell and tissue protocols involving a patient's adult stem cells (non-embryonic), enabling them to undergo cellular-based treatments.
Related Insight
Suppliers Directory
Softbox - Temperature Control Packaging Systems
Softbox design and manufacture temperature control packaging and cold chain - shipping containers for the distribution of biotech, biomedical, clinical trial and finished pharmaceutical products.
Production & Manufacturing > Manufacturing > Suppliers
TBM Consulting Group - Lean Sigma Manufacturing Services
The global fallout from the real estate and banking crisis has impacted economies worldwide since 2009 and is likely to carry over well into 2012. The drop in consumer demand, capital spending cuts, layoffs, rising unemployment, the spectre of inflation and erratic equity markets has put intense pressure on margins and heightened everyone’s focus on cutting costs.
Production & Manufacturing > Manufacturing > Suppliers
FlexLink - Production Logistics Systems Provider
FlexLink production logistics solutions allow manufacturers to achieve full production efficiency. For more than 30 years, FlexLink has provided production logistics solutions to worldwide manufacturing industries.
Production & Manufacturing > Manufacturing > Suppliers
Fios Genomics - Genomic and Bioinformatic Data Analysis Services
Fios Genomics provides an extensive range of genomic and bioinformatic data analysis services for Pharma, CROs and academic & clinical research for applications in drug discovery & development for both human and animal health.
Production & Manufacturing > Manufacturing > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Manufacturing Intelligence
Product Overview
Published by Burkert Fluid Control Systems
Production & Manufacturing > Manufacturing > White Papers
Biomarker Solutions
Published by Randox
Production & Manufacturing > Manufacturing > White Papers
Reducing Analysis Limitations by Using Multiple Detectors with Ultra-Fast LC
Published by Shimadzu PBR
Production & Manufacturing > Manufacturing > White Papers
Building Blocks For Click Chemistry
Published by IRIS Biotech
Production & Manufacturing > Manufacturing > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.